Statin Therapy
Statin use may lead to ‘unintended consequence’ of insulin resistance
A cohort of Canadian adults prescribed statins, and hydrophilic statins, in particular, had higher levels of insulin resistance compared with non-statin users, according to findings published in the Journal of the Endocrine Society.
Top news of May: BP control via medication reduction, dapagliflozin approval and more
Healio and Cardiology Today have compiled a list of the top cardiology news from the month of May.
Some CV medications prescribed less often to women than men
Women with established CVD had lower rates of prescriptions for statins, aspirin and ACE inhibitors compared with men, according to a systematic review and meta-analysis published in the Journal of the American Heart Association.
Icosapent ethyl reduces revascularization events: REDUCE-IT REVASC
A prespecified analysis of the REDUCE-IT trial highlighted a reduction in first and total revascularization events with icosapent ethyl in patients with elevated triglycerides at high CV risk despite statin therapy.
Evolocumab safe, effective for LDL lowering in patients living with HIV
In patients living with HIV, the PCSK9 inhibitor evolocumab significantly reduced LDL levels compared with placebo and was well tolerated, according to the results of the BEIJERINCK randomized, double-blind trial.
AHA: Aggressive treatment may benefit patients with diabetes, CAD
The treatment of CAD in patients with type 2 diabetes may need to be more aggressive compared with those without diabetes to reduce the risk for MI and other complications, according to an American Heart Association scientific statement published in Circulation.
Statins may reduce HF hospitalization after chemotherapy for breast cancer
Among women undergoing chemotherapy for early-stage breast cancer, statin exposure reduced risk for hospitalization due to HF by up to 66%, according to a retrospective population-based cohort study presented at the American College of Cardiology Scientific Session.
FDA approves bempedoic acid/ezetimibe for LDL lowering in ASCVD, HeFH
Esperion Therapeutics announced that a medication combining bempedoic acid and ezetimibe to lower LDL in adults with heterozygous familial hypercholesterolemia or established atherosclerotic CVD has been approved by the FDA.
Oral statins may improve PASI score in patients with severe psoriasis
FDA approves bempedoic acid for LDL lowering in high-risk populations
The FDA has approved bempedoic acid for reducing LDL as an adjunct to diet and maximally tolerated statin therapy in patients with heterozygous familial hypercholesterolemia or established atherosclerotic CVD, according to the agency’s website and an alert from Esperion Therapeutics.